fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ezetimibe

All products: Limited Use (codes 380, 381)

Ran-Ezetimibe · DIN 02419548 · 10 mg · tablet

Limited Use, Reason for Use code 380, 381 requiredMarketed · checked November 20, 2026
StatusLimited Use, Reason for Use code 380, 381 required
Write on scriptone applicable Reason for Use code, 380 or 381 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 380, 381
Reason for Use code 380 For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 381 For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Ezetimibe · DIN 02419548 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2014-11-27 Health Canada: Marketed since 2026-03-11 · brand SPC-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ran-Ezetimibe: Formulary list price $0.18 per unit (the source does not state the unit; exact figure $0.1811). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02419548)

Source record
DIN 02419548: Ran-Ezetimibe Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id RAN Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1811; ministry $0.1811 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02419548 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90416
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811 Ach-Ezetimibe · DIN 02425610 · $0.1811 Act Ezetimibe · DIN 02414716 · $0.1811 Apo-Ezetimibe · DIN 02427826 · $0.1811 Auro-Ezetimibe · DIN 02469286 · $0.1811 Bio-Ezetimibe · DIN 02425211 · $0.1811 Ezetimibe · DIN 02429659 · $0.1811 Ezetimibe · DIN 02431300 · $0.1811 Ezetrol · DIN 02247521 · $0.1811 GLN-Ezetimibe · DIN 02460750 · $0.1811 Jamp-Ezetimibe · DIN 02423235 · $0.1811 M-Ezetimibe · DIN 02467437 · $0.1811 Mar-Ezetimibe · DIN 02422662 · $0.1811 Mint-Ezetimibe · DIN 02423243 · $0.1811 NRA-Ezetimibe · DIN 02481669 · $0.1811 NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811 PMS-Ezetimibe · DIN 02416409 · $0.1811 Sandoz Ezetimibe · DIN 02416778 · $0.1811 Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (C10A, C10AX): coverage varies; not interchangeable

  • Alirocumab (Praluent): limited Use 555
  • Evolocumab (Repatha): limited Use 527, 737
  • Inclisiran (Leqvio): limited Use 732
  • Atorvastatin (Lipitor): general benefit
  • Bezafibrate (Bezalip): general benefit
  • Cholestyramine resin (Questran Light 4g Pk): general benefit, not a benefit

9 more in the class list below

Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:06 Antilipemic Drugs

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 84 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication:
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. AMBRISENTAN · Off-Formulary Interchangeable, not an ODB benefit Indications VOLIBRIS (ambrisentan tablets) is indicated for: • The treatment of idiopathic (‘primary’) pulmonary arterial hypertension (IPAH) and pulmonary arterial hypertension (PAH) associated with connective tissue disease in adult patients with WHO functional class II or III symptoms. PM: https://pdf.hres.ca/dpd_pm/00082650.PDF; date 2025-12-02; DIN 02307065; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS EZETROL® (ezetimibe) is indicated as an adjunct to lifestyle changes, including diet, when the response to diet and other non-pharmacological measures alone has been inadequate. Primary Hypercholesterolemia EZETROL, administered alone or with an HMG-CoA reductase inhibitor (statin), is indicated for: • the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL C), apolipoprotein B (Apo B), and triglycerides (TG) and • to increase high density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. EZETROL, administered in combination with fenofibrate, is indicated for: • the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia. Homozygous Familial Hypercholesterolemia (HoFH) EZETROL, administered with a statin, is indicated for: • the reduction of elevated total-C and LDL-C levels in patients with HoFH as an adjunct to treatments such as LDL apheresis or if such treatments are not possible. Homozygous Sitosterolemia (Phytosterolemia) EZETROL is indicated for: • the reduction of… https://pdf.hres.ca/dpd_pm/00074278.PDF PM date: JUN 15, 2003 Source product: EZETROL; DIN 02247521; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18